Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine...
Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study
About this item
Full title
Author / Creator
Braat, Arthur J A T, MD , Bruijnen, Rutger C G, MD , van Rooij, Rob, PhD , Braat, Manon N G J A, MD , Wessels, Frank J, MD , van Leeuwaarde, Rachel S, MD , van Treijen, Mark J C, MD , de Herder, Wouter W, Prof , Hofland, Johannes, MD , Tesselaar, Margot E T, MD , de Jong, Hugo W A M, Prof and Lam, Marnix G E H, Prof
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
SummaryBackgroundIn patients with metastatic neuroendocrine neoplasms, the liver is the most commonly affected organ and a crucial factor for prognosis and survival. Peptide receptor radionuclide therapy can prolong progression-free survival in these patients. Additional treatment of liver disease might further improve outcomes. We aimed to investi...
Alternative Titles
Full title
Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2369399252
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2369399252
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(20)30027-9
